VINCENT RICHARD G 4

What Happened
Vincent Richard G, a director of Forte Biosciences, was granted 18,353 restricted stock units (RSUs) on May 29, 2026. The award is reported as an acquisition of a derivative security at $0.00 (reported value $0); each RSU represents a contingent right to one share of common stock. This is a grant/award (not an open‑market purchase or sale).

Key Details

• Transaction type/code: Award/Grant (Code A), derivative security (RSUs).
• Date of transaction: 2026-05-29; Form 4 filed 2026-06-02 (within the SEC’s 2-business-day reporting window).
• Amount: 18,353 RSUs; reported acquisition price $0.00 (typical for RSU grants).
• Shares owned after transaction: Not specified in this filing.
• Footnotes: F1 — Each RSU converts to one share of common stock. F2 — 100% of the RSUs vest on the date of the first annual stockholders’ meeting after May 29, 2026, provided the reporting person remains a service provider.

Context
RSU grants to directors are a common form of compensation and do not represent an immediate cash purchase or sale. Vesting is contingent on continued service and a future event (the next annual meeting), so the award does not immediately increase tradable shares. This filing is informational and should not be taken as a direct buy/sell signal.